<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535937</url>
  </required_header>
  <id_info>
    <org_study_id>#6403/7339R</org_study_id>
    <secondary_id>1K23DA031771-01</secondary_id>
    <nct_id>NCT01535937</nct_id>
  </id_info>
  <brief_title>The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will evaluate the effect of a single sub-anesthetic dose of ketamine on the time
      to first cocaine use and abstinence rates in 60 treatment-seeking cocaine-dependent
      individuals receiving mindfulness-based relapse prevention (MBRP) therapy, using a 5 week
      combined laboratory-inpatient and outpatient double-blind, randomized, controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      he study will begin with an inpatient phase (phase 1) of 5 days, during which abstinence is
      achieved, followed by a 4 week outpatient phase (phase 2). A single infusion of ketamine or
      midazolam will occur on day 3 of Phase 1. In addition to measures of mindfulness and
      impulsivity, stress sensitivity tests are incorporated into the design in order to elucidate
      mechanisms of action. The study hypotheses are:

        1. ketamine and MBRP will significantly increase the time to first use compared to placebo
           and MBRP in cocaine-dependent individuals.

        2. ketamine and MBRP is significantly more likely to lead to abstinence from cocaine (no
           use over one week) as compared to placebo and MBRP.

        3. ketamine and MBRP will significantly reduce subjective, endocrine, and physiological
           responses to stress (including cue exposure) as compared to placebo and MBRP.

        4. ketamine and MBRP will significantly increase mindfulness, as assessed by the Five Facet
           Mindfulness Questionnaire (FFMQ), as compared to placebo and MBRP.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    An analysis demonstrated that running the final participants was unnecessary.
  </why_stopped>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Cocaine Use/Drop Out</measure>
    <time_frame>Over the four week period following discharge from the inpatient unit at Day 5</time_frame>
    <description>Number of participants who use cocaine and drop from study. During phase 2, patients will be assessed twice weekly by TLFB and urine toxicology for cocaine use. The day of first use will determine the length of time that transpired from discharge to the first lapse onto cocaine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence</measure>
    <time_frame>Abstinence will be assessed over 4 weeks starting at the last day of week 1 and continuing through the end of study at the last day of week 5</time_frame>
    <description>Abstinence is defined as 2 or greater weeks of no cocaine use, as ascertained by the TLFB and urine toxicology.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg of ketamine IV over 40 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.025 mg/kg IV over 40 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.5 mg/kg IV over 40 minutes</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>ketamine 0.5 mg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>0.025 mg/kg IV over 40 minutes</description>
    <arm_group_label>midazolam</arm_group_label>
    <other_name>midazolam 0.025 mg/kg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active cocaine dependence with at least 8 days of use or at least 4 binges of large
             amounts (&gt;$200/occasion) over the past 30 days, and displaying at least one positive
             utox during screening

          -  Physically healthy

          -  No adverse reactions to study medications

          -  21-60 years of age

          -  Capacity to consent and comply with study procedures, including sufficient proficiency
             in English

          -  Seeking treatment

        Exclusion Criteria:

          -  Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia,
             any psychotic illness, including substance induced psychosis, and current
             substance-induced mood disorder with HAMD score &gt; 12.

          -  Physiological dependence on another substance requiring medical management, such as
             alcohol, opioids, or benzodiazepines, excluding caffeine, nicotine, and cannabis

          -  Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders

          -  Current suicide risk or a history of suicide attempt within the past year

          -  Pregnant or interested in becoming pregnant during the study period

          -  Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.

          -  Unstable physical disorders which might make participation hazardous such as end-stage
             AIDS, hypertension (&gt;140/90), WBC &lt; 3.5, active hepatitis or other liver disease with
             elevated transaminase levels (&lt; 2-3 X upper limit of normal will be considered
             acceptable if PT/PTT is normal), renal failure (creatinine &gt; 2, BUN &gt;40), or untreated
             diabetes

          -  Previous history of ketamine or benzodiazepine misuse or abuse, and a history of an
             adverse reaction/experience with prior exposure to ketamine or benzodiazepine

          -  Recent history of significant violence (past 2 years)

          -  First degree relative with a psychotic disorder (bipolar disorder, schizophrenia,
             schizoaffective disorder, or psychosis NOS)

          -  BMI &gt; 32, or a history of documented obstructive sleep apnea

          -  On psychotropic or other medications whose effect could be disrupted by participation
             in the study

          -  Patients who cannot comply with study procedures during the initial hospitalization
             phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Kleber, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>NYSPI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elias Dakwar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 29, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <results_first_submitted>April 12, 2018</results_first_submitted>
  <results_first_submitted_qc>August 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Elias Dakwar</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>0.5 mg/kg of ketamine IV over 40 minutes
Ketamine: 0.5 mg/kg IV over 40 minutes</description>
        </group>
        <group group_id="P2">
          <title>Midazolam</title>
          <description>0.025 mg/kg IV over 40 minutes
Midazolam: 0.025 mg/kg IV over 40 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>0.5 mg/kg of ketamine IV over 40 minutes
Ketamine: 0.5 mg/kg IV over 40 minutes</description>
        </group>
        <group group_id="B2">
          <title>Midazolam</title>
          <description>0.025 mg/kg IV over 40 minutes
Midazolam: 0.025 mg/kg IV over 40 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="2"/>
                    <measurement group_id="B2" value="49" spread="1"/>
                    <measurement group_id="B3" value="47" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cocaine Use/Drop Out</title>
        <description>Number of participants who use cocaine and drop from study. During phase 2, patients will be assessed twice weekly by TLFB and urine toxicology for cocaine use. The day of first use will determine the length of time that transpired from discharge to the first lapse onto cocaine.</description>
        <time_frame>Over the four week period following discharge from the inpatient unit at Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>0.5 mg/kg of ketamine IV over 40 minutes
Ketamine: 0.5 mg/kg IV over 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>0.025 mg/kg IV over 40 minutes
Midazolam: 0.025 mg/kg IV over 40 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cocaine Use/Drop Out</title>
          <description>Number of participants who use cocaine and drop from study. During phase 2, patients will be assessed twice weekly by TLFB and urine toxicology for cocaine use. The day of first use will determine the length of time that transpired from discharge to the first lapse onto cocaine.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Abstinence</title>
        <description>Abstinence is defined as 2 or greater weeks of no cocaine use, as ascertained by the TLFB and urine toxicology.</description>
        <time_frame>Abstinence will be assessed over 4 weeks starting at the last day of week 1 and continuing through the end of study at the last day of week 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>0.5 mg/kg of ketamine IV over 40 minutes
Ketamine: 0.5 mg/kg IV over 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>0.025 mg/kg IV over 40 minutes
Midazolam: 0.025 mg/kg IV over 40 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Abstinence</title>
          <description>Abstinence is defined as 2 or greater weeks of no cocaine use, as ascertained by the TLFB and urine toxicology.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>0.5 mg/kg of ketamine IV over 40 minutes
Ketamine: 0.5 mg/kg IV over 40 minutes</description>
        </group>
        <group group_id="E2">
          <title>Midazolam</title>
          <description>0.025 mg/kg IV over 40 minutes
Midazolam: 0.025 mg/kg IV over 40 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <description>sedation persisting for more than 1 hour post-infusion</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elias Dakwar, MD</name_or_title>
      <organization>NYSPI</organization>
      <phone>646.774.8728</phone>
      <email>elias.dakwar@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

